Long-term outcomes of unani and allopathic therapy in oral submucous fibrosis
Bioinformation · 31.10.2026 · 22 (10) · 6509-6516
DOI: 10.6026/973206300226509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioinformation, online erschienen am 31.10.2026. Verfasst von Arpita Rai.
Abstract (Originalsprache)
Oral submucous fibrosis (OSMF) is a chronic, progressive and potentially malignant disorder with limited evidence on the long-term sustainability of treatment outcomes. This prospective longitudinal study evaluated 12-month outcomes of Unani formulations versus conventional allopathic antioxidant therapy following completion of a randomized controlled trial. Participants received treatment for 12 weeks and were followed for 12 months without additional intervention, with disease status and oral health-related quality of life (OHRQoL) assessed using predefined criteria and the OPMDQoL questionnaire. Among 88 participants (45 Unani and 43 allopathy), stable disease predominated (66.7% vs. 56.5%), with no significant between-group differences (all P > 0.05), while OHRQoL improved significantly within the Unani group (P = 0.001). Thus, unani formulations and allopathic antioxidant therapy showed comparable 12-month outcomes, maintaining disease stability and improving OHRQoL.
Zitieren
APA
Rai, A. (2026). Long-term outcomes of unani and allopathic therapy in oral submucous fibrosis. Bioinformation, 22(10), 6509-6516. https://doi.org/10.6026/973206300226509
Vancouver
Rai A. Long-term outcomes of unani and allopathic therapy in oral submucous fibrosis. Bioinformation. 2026;22(10):6509-6516. doi:10.6026/973206300226509
BibTeX
@article{Rai2026,
author = {Rai, Arpita},
title = {Long-term outcomes of unani and allopathic therapy in oral submucous fibrosis},
journal = {Bioinformation},
year = {2026},
volume = {22},
number = {10},
pages = {6509--6516},
doi = {10.6026/973206300226509}
}
EUVIMED